PRTK | Paratek Pharmaceuticals, Inc. | [NASD]
Index- P/E- EPS (ttm)-1.19 Insider Own7.10% Shs Outstand56.90M Perf Week-13.19%
Market Cap92.79M Forward P/E- EPS next Y-0.08 Insider Trans13.27% Shs Float46.32M Perf Month3.95%
Income-65.80M PEG- EPS next Q-0.33 Inst Own46.40% Short Float / Ratio9.61% / 6.09 Perf Quarter-8.67%
Sales166.60M P/S0.56 EPS this Y4.20% Inst Trans2.03% Short Interest4.45M Perf Half Y-28.83%
Book/sh-3.32 P/B- EPS next Y91.50% ROA-40.80% Target Price5.33 Perf Year-9.20%
Cash/sh- P/C- EPS next 5Y- ROE39.00% 52W Range1.29 - 3.65 Perf YTD-15.51%
Dividend- P/FCF- EPS past 5Y18.80% ROI-53.90% 52W High-56.71% Beta1.58
Dividend %- Quick Ratio3.00 Sales past 5Y66.30% Gross Margin84.50% 52W Low22.48% ATR0.16
Employees268 Current Ratio3.40 Sales Q/Q25.30% Oper. Margin-29.00% RSI (14)38.62 Volatility6.70% 8.24%
OptionableYes Debt/Eq- EPS Q/Q-3.10% Profit Margin-39.50% Rel Volume0.20 Prev Close1.62
ShortableYes LT Debt/Eq- EarningsMay 09 AMC Payout- Avg Volume730.76K Price1.58
Recom1.30 SMA20-10.58% SMA50-21.33% SMA200-30.17% Volume145,541 Change-2.47%
Date Action Analyst Rating Change Price Target Change
May-02-23Resumed Jefferies Buy $7 → $5
Apr-17-23Resumed BTIG Research Buy $24
Feb-10-22Upgrade WBB Securities Buy → Strong Buy $11
Apr-23-21Upgrade WBB Securities Speculative Buy → Buy $6 → $10
Mar-02-21Initiated Jefferies Buy $15
Nov-09-20Reiterated H.C. Wainwright Buy $19 → $22
Jan-08-20Initiated WBB Securities Speculative Buy $6
Jan-02-19Initiated Canaccord Genuity Buy $14
Nov-23-18Reiterated H.C. Wainwright Buy $55 → $22
Aug-27-18Initiated BofA/Merrill Neutral $13
May-15-23 11:26AM
May-10-23 03:31PM
May-09-23 05:45PM
04:05PM Loading…
May-01-23 08:30AM
Apr-17-23 06:13AM
Apr-10-23 07:30AM
Mar-18-23 02:03AM
Mar-16-23 10:12PM
Mar-08-23 08:30AM
04:05PM Loading…
Mar-01-23 04:05PM
Feb-23-23 10:52AM
Feb-01-23 04:05PM
Jan-18-23 07:00AM
Jan-05-23 08:00AM
Jan-02-23 10:50AM
Dec-20-22 07:30AM
Dec-19-22 07:30AM
Dec-01-22 05:45PM
Nov-21-22 04:05PM
Nov-09-22 05:32AM
Nov-03-22 05:45PM
Nov-01-22 04:05PM
08:00AM Loading…
Oct-31-22 08:00AM
Oct-25-22 08:00AM
Oct-13-22 04:05PM
Oct-03-22 04:05PM
Sep-26-22 08:30AM
Sep-16-22 11:12AM
Sep-01-22 04:05PM
Aug-04-22 01:30AM
Aug-03-22 05:25PM
Aug-01-22 04:05PM
Jul-25-22 04:05PM
Jul-18-22 09:32AM
Jul-01-22 04:05PM
Jun-21-22 04:05PM
Jun-08-22 07:10AM
Jun-01-22 04:15PM
May-16-22 04:05PM
May-05-22 12:30PM
May-04-22 04:05PM
May-02-22 04:05PM
Apr-26-22 04:05PM
Apr-09-22 10:49AM
Apr-01-22 04:05PM
Mar-14-22 12:30PM
Mar-08-22 04:05PM
Mar-02-22 04:05PM
Mar-01-22 04:05PM
Feb-08-22 09:36AM
Feb-03-22 05:38PM
Feb-01-22 09:38PM
Jan-03-22 04:05PM
Dec-16-21 11:36AM
Dec-10-21 08:36AM
Dec-05-21 03:30AM
Dec-01-21 04:05PM
Nov-10-21 04:05PM
Nov-08-21 06:05PM
Nov-01-21 04:05PM
Oct-28-21 03:05PM
Oct-18-21 04:05PM
Oct-11-21 01:11PM
Oct-01-21 04:05PM
Sep-30-21 08:00AM
Sep-28-21 08:24AM
Sep-27-21 04:05PM
Sep-24-21 11:44AM
Sep-23-21 04:05PM
Sep-09-21 08:30AM
Sep-01-21 04:05PM
Aug-19-21 12:14PM
Aug-18-21 04:12PM
Aug-10-21 04:25AM
Aug-09-21 05:35PM
Aug-05-21 08:00AM
Aug-04-21 04:30PM
Aug-03-21 04:30PM
Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. Its products include NUZYRA, a once-daily oral and intravenous broad-spectrum antibiotic for the treatment of adult patients with community-acquired bacterial pneumonia, and acute skin and skin structure infections caused by susceptible pathogens; and SEYSARA, a once-daily oral therapy for the treatment of moderate to severe acne vulgaris. The company has license and collaboration agreements with Zai Lab (Shanghai) Co., Ltd. and Allergan plc; license agreement with Tufts University to develop and commercialize products for the treatment or prevention of bacterial or microbial diseases, or medical conditions; and contract with Biomedical Advanced Research and Development Authority to support the development of NUZYRA for the treatment of pulmonary anthrax. It also has license agreement with Tetraphase Pharmaceuticals, Inc. to develop, import, and sell the XERAVATM product, which is used for the treatment of complicated intra-abdominal infections caused by bacteria. The company was founded in 1996 and is headquartered in Boston, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
DONDERO JAMES D10% OwnerMar 23Buy1.73100,000173,0002,156,000Mar 29 04:31 PM
DONDERO JAMES D10% OwnerMar 22Buy1.77106,000187,6202,056,000Mar 29 04:31 PM
DONDERO JAMES D10% OwnerMar 21Buy1.74242,500421,9501,307,617Mar 29 04:31 PM
DONDERO JAMES D10% OwnerMar 20Buy1.40105,137147,1922,239,770Mar 29 04:31 PM
DONDERO JAMES D10% OwnerMar 17Buy1.50234,863352,2942,134,663Mar 29 04:31 PM
Stein JeffreyDirectorFeb 21Sale1.907,00013,30068,625Feb 23 02:27 PM
Franson Timothy RDirectorFeb 21Sale1.887,00013,16072,000Feb 23 02:22 PM
Loh EvanCEODec 21Sale1.9923,48946,7431,208,198Dec 22 04:44 PM
BIGHAM MICHAELExec. Chairman of the BoardDec 21Sale1.9915,75031,3421,209,702Dec 22 04:26 PM
Haskel William M.CLO, General Counsel & Sec.Dec 21Sale1.997,00713,944407,800Dec 22 04:38 PM
Woodrow AdamPresident & Chief CommercialDec 21Sale1.996,75013,432651,284Dec 22 04:51 PM
Brenner Randall B.Chief Development & RegulatoryDec 21Sale1.994,5399,033335,312Dec 22 04:33 PM
Loh EvanCEODec 13Sale1.9661,919121,3611,179,187Dec 14 08:08 PM
BIGHAM MICHAELExec. Chairman of the BoardDec 13Sale1.9631,89162,5061,180,452Dec 14 08:00 PM
Haskel William M.CLO, General Counsel & Sec.Dec 13Sale1.9623,58446,225399,807Dec 14 08:05 PM
Brenner Randall B.Chief Development & RegulatoryDec 13Sale1.9618,17735,627324,851Dec 14 08:03 PM
Woodrow AdamPresident & Chief CommercialDec 13Sale1.966,25312,256635,534Dec 14 08:11 PM
Loh EvanCEODec 12Sale1.9837,83174,9051,241,106Dec 14 08:08 PM
BIGHAM MICHAELExec. Chairman of the BoardDec 12Sale1.9819,48438,5781,212,343Dec 14 08:00 PM
Haskel William M.CLO, General Counsel & Sec.Dec 12Sale1.9814,41028,532423,391Dec 14 08:05 PM
Brenner Randall B.Chief Development & RegulatoryDec 12Sale1.9811,10521,988343,028Dec 14 08:03 PM
Woodrow AdamPresident & Chief CommercialDec 12Sale1.983,8207,564641,787Dec 14 08:11 PM
Loh EvanCEOOct 28Sale3.478,80530,5531,278,937Nov 01 07:58 PM
BIGHAM MICHAELExec. Chairman of the BoardOct 28Sale3.476,00020,8201,231,827Nov 01 07:51 PM
Woodrow AdamPresident & Chief CommercialOct 28Sale3.474,56315,834645,607Nov 01 08:00 PM
Haskel William M.CLO, General Counsel & Sec.Oct 28Sale3.474,38215,206437,801Nov 01 07:55 PM
Brenner Randall B.Chief Development & RegulatoryOct 28Sale3.473,51612,201354,133Nov 01 07:53 PM
Loh EvanCEOAug 09Sale2.6644,519118,4211,257,742Aug 10 09:06 PM
BIGHAM MICHAELExec. Chairman of the BoardAug 09Sale2.6628,63776,1741,207,827Aug 10 09:00 PM
Haskel William M.CLO, General Counsel & Sec.Aug 09Sale2.6622,45359,725432,933Aug 10 09:04 PM
Brenner Randall B.Chief Development & RegulatoryAug 09Sale2.6619,60852,157349,149Aug 10 09:02 PM